抗血管平滑肌增生和迁移的药物涂层与支架置入后再狭窄

背景：抑制血管平滑肌细胞增殖和血管内膜的增生而不影响血管内皮愈合的药物涂层是研制新型药物洗脱支架和防治支架内再狭窄的新策略。目的：综述抗血管平滑肌细胞增生和迁移药物涂层支架的研究进展。方法：由第一作者应用计算机检索维普数据库中与抗血管平滑肌细胞增生和迁移药物涂层支架置入治疗心血管疾病有关的文献,检索时限1998-01/2011-10。关键词：心血管疾病;药物涂层支架;血管平滑肌;细胞增生;细胞迁移。对资料进行初审,并查看每篇文献后的引文。纳入相关文献25篇,中文15篇,英文10篇。结果与结论：目前临床应用最广的抗血管平滑肌细胞增生和迁移的涂层药物是雷帕霉素和紫杉醇。研究表明,雷帕霉素支架表面携带的雷帕霉素和紫杉醇支架表面携带的紫杉醇均能有效地降低支架置入后再狭窄及临床靶血管血运重建率。目前国内大多数研究仅为小样本、单中心、非随机对照试验,其更长期的疗效和安全性有待更长期的随访和多中心随机对照研究来证明。

Drug eluting against vascular smooth muscle proliferation and migration for in-stent restenosis

BACKGROUND：Drug eluting that can inhibit vascular smooth muscle cells proliferation and neointimal hyperplasia,with no affection on vascular endothelial healing is a new strategy to develop novel drug eluting stent and to prevent in-stent restenosis.OBJECTIVE：To summarize advanced progress on drug-eluting stent that prevents vascular smooth muscle cell proliferation and migration.METHODS：An online computer-based retrieval was performed by the first author on VIP database for articles regarding the drug-eluting stent of anti-vascular smooth muscle cells proliferation and migration in the treatment of cardiovascular disease,retrieval time ranged from January 1998 to October 2011.Key words were ＂cardiovascular diseases;drug-eluting stents;vascular smooth muscle cells;cell proliferation;cell migration＂ in Chinese.After the primary screening,all citations of each literature were checked.A total of 25 literatures were involved,including 15 Chinese and 10 English.RESULTS AND CONCLUSION：The currently used eluting drugs of anti-vascular smooth muscle cells proliferation and migration are rapamycin and paclitaxel.An increasing number of studies show that,rapamycin and paclitaxel in corresponding stents can both effectively reduce restenosis after stent implantation and rate of target vessel blood supply revascularization in clinical practice.Most of the current domestic research are small sample size,single-center,non-randomized controlled trials,and long-term efficacy and safety need to longer-term follow-ups and multicenter randomized controlled study.